INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2015

Neither EPA-enriched nor DHA-enriched omega-3 fatty acids were superior to placebo for treating major depressive disorder.

A 2-site trial randomized 196 adults with DSM-IV major depressive disorder to 8 weeks of EPA-enriched omega-3 (1,000 mg/d), DHA-enriched omega-3 (1,000 mg/d), or placebo. All three groups exhibited statistically significant improvements in HDRS-17, QIDS-SR-16, and CGI-S scores (P < .05), but neither active preparation separated significantly from placebo (P > .05). Response rates were 40%-50% and remission rates were approximately 30% across all treatments without significant differences between groups.

Study type
Double-blind, placebo-controlled, randomized clinical trial
Who was studied
196 adults with DSM-IV major depressive disorder and baseline HDRS-17 score ≥ 15
What was measured
Change in HDRS-17, QIDS-SR-16, and CGI-S scores, response, and remission rates

THE PAPER

A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression.

Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M. J Clin Psychiatry, 2015.

PubMed 25272149 ↗DOI 10.4088/jcp.14m08986 ↗

Nutrients & adequacyBrain & mood

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.